Viking Therapeutics' drug results were less favorable than Eli Lilly's, leading to speculation that Viking may seek a partnership or acquisition.
3 reports, 3 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics' drug results were less favorable than Eli Lilly's, leading to speculation that Viking may seek a partnership or acquisition.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK and Viking Therapeutics are seeking updates on potential collaboration prospects for drugs targeting NASH and X-ALD.Sub-event
Viking's drug results underperformed Eli Lilly's, prompting M&A interest.1 source
Eli Lilly's clinical setback impacts the competitive landscape with Viking Therapeutics.1 source
Keep exploring
Part of
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Also in this story
- Pfizer acquired Metsera after a bidding war with Novo Nordisk.
- Pfizer CEO Albert Bourla discussed company performance driven by cost control and AI, while UBS pressed on government policy impacts.
- Institutional investor Stanley Druckenmiller's firm must file Form 13F with the SEC regarding its new position in Viking Therapeutics, amidst market competition among weight loss drug companies.
- Eli Lilly and Novo Nordisk faced legal actions and partnership terminations regarding compliance and customer deception.
The entities involved
-
Viking Therapeutics
company in San Diego, United States
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Viking Therapeutics and NextCure, both clinical-stage biopharma companies, are being compared on affordability and analyst ratings.
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Coverage
Newest first; wire copies grouped- fool.com
- Motley FoolHere's Why Viking Therapeutics Bounced Back Today The safety and tolerability data were at odds with an earlier phase 1 trial, and not as good as a comparable drug trial result from Eli Lilly. Viking
- BenzingaViking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch